From our list 18 new health tech startups in Europe worth knowing (2026)
Breye Therapeutics, from Denmark, develops oral medicines for early-stage retinal diseases, starting with diabetic retinopathy. Founded in 2019 and led by CEO Ulrik Mouritzen, it announced an oversubscribed 67.5 million euro Series A led by Mission BioCapital and Novo Holdings on 2 October 2026, to take its lead candidate into Phase 2 trials planned for 2027. Website: breye.com. Source: EU-Startups. Also in our list: European startups that raised money, 28 September to 2 October 2026.
Questions about Breye Therapeutics
What does Breye Therapeutics do?
Breye Therapeutics: a pill for early diabetic eye disease.
Where is Breye Therapeutics based?
Breye Therapeutics is based in Denmark.
Where can I read more about Breye Therapeutics?
Breye Therapeutics is in our list 18 new health tech startups in Europe worth knowing (2026): https://meetnewbrands.com/articles/new-health-tech-startups-in-europe-2026